HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy

Nature Medicine

Volumn 23, Issue 5, 2017, Pages 638-643

  Honeycutt, Jenna B ^a   Thayer, William O ^a   Baker, Caroline E ^a   Ribeiro, Ruy M ^b   Lada, Steven M ^c   Cao, Youfang ^b   Cleary, Rachel A ^a   Hudgens, Michael G ^d   Richman, Douglas D ^c,e,f   Victor Garcia, J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LACTONE; NG 011; NR4A2 PROTEIN, HUMAN; NUCLEAR RECEPTOR RELATED FACTOR 1; PHENOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIRETROVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERSISTENT VIRUS INFECTION; POINT MUTATION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; BONE MARROW; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOHISTOCHEMISTRY; LIVER; LUNG ALVEOLUS MACROPHAGE; MONONUCLEAR CELL; PHYSIOLOGY; PULSED FIELD GEL ELECTROPHORESIS; SPLEEN; VIROLOGY; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE MARROW; DNA, VIRAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; LEUKOCYTES, MONONUCLEAR; LIVER; MACROPHAGES; MACROPHAGES, ALVEOLAR; MICE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PHENOLS; RNA, VIRAL; SPLEEN; T-LYMPHOCYTES; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 85017503329     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4319     Document Type: Article

References (39)

1. Kumar, A. & Herbein, G. The macrophage: a therapeutic target in HIV-1 infection. Mol. Cell. Ther. 2, 10 (2014).
2. Koppensteiner, H., Brack-Werner, R. & Schindler, M. Macrophages and their relevance in human immunodeficiency virus type I infection. Retrovirology 9, 82 (2012).
3. Campbell, J. H., Hearps, A. C., Martin, G. E., Williams, K. C. & Crowe, S. M. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 28, 2175-2187 (2014).
4. Sattentau, Q. J. & Stevenson, M. Macrophages and HIV-1: an unhealthy constellation. Cell Host Microbe 19, 304-310 (2016).
5. Collman, R. G., Perno, C. F., Crowe, S. M., Stevenson, M. & Montaner, L. J. HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J. Leukoc. Biol. 74, 631-634 (2003).
6. Gavegnano, C. & Schinazi, R. F. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir. Chem. Chemother. 20, 63-78 (2009).
7. Honeycutt, J. B. et al. Macrophages sustain HIV replication in vivo independently of T cells. J. Clin. Invest. 126, 1353-1366 (2016).
8. Denton, P. W. et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 5, e8829 (2010).
9. Wahl, A. et al. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 8, e1002732 (2012).
10. Olesen, R., Wahl, A., Denton, P. W. & Garcia, J. V. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J. Reprod. Immunol. 88, 195-203 (2011).
11. Melkus, M. W. et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 12, 1316-1322 (2006).
12. Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630-634 (2012).
13. Denton, P. W. et al. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 10, e1003872 (2014).
14. Thompson, M. A. et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. J. Am. Med. Assoc. 308, 387-402 (2012).
15. Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
16. Ho, D. D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
17. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
18. Calin, R. et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS 30, 761-769 (2016).
19. Shultz, L. D., Ishikawa, F. & Greiner, D. L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7, 118-130 (2007).
20. Igarashi, T. et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98, 658-663 (2001).
21. Micci, L. et al. CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLoS Pathog. 10, e1004467 (2014).
22. Avalos, C. R. et al. Quantitation of productively infected monocytes and macrophages of simian immunodeficiency virus-infected macaques. J. Virol. 90, 5643-5656 (2016).
23. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
24. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
25. Sung, J. A. et al. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J. Infect. Dis. 212, 258-263 (2015).
26. Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 22, 1131-1135 (2008).
27. Spina, C. A. et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 9, e1003834 (2013).
28. Prochazka, M., Gaskins, H. R., Shultz, L. D. & Leiter, E. H. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc. Natl. Acad. Sci. USA 89, 3290-3294 (1992).
29. Hill, A. L. et al. Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV. PLoS Pathog. 12, e1005535 (2016).
30. Steingrover, R. et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 22, 1583-1588 (2008).
31. Persaud, D. et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835 (2013).
32. Henrich, T. J. et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 207, 1694-1702 (2013).
33. Nath, A. & Clements, J. E. Eradication of HIV from the brain: reasons for pause. AIDS 25, 577-580 (2011).
34. Joseph, S. B., Arrildt, K. T., Sturdevant, C. B. & Swanstrom, R. HIV-1 target cells in the CNS. J. Neurovirol. 21, 276-289 (2015).
35. Strain, M. C. et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 8, e55943 (2013).
36. Honeycutt, J. B. et al. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 10, 121 (2013).
37. Zhang, D., Fan, C., Zhang, J. & Zhang, C. H. Nonparametric methods for measurements below detection limit. Stat. Med. 28, 700-715 (2009).
38. Lafleur, B. et al. Statistical methods for assays with limits of detection: serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. J. Carcinog. 10, 12 (2011).
39. Gillespie, B. W. et al. Estimating population distributions when some data are below a limit of detection by using a reverse Kaplan-Meier estimator. Epidemiology 21 (Suppl. 4), S64-S70 (2010).